This is a repository copy of *Comparison and optimisation of microRNA extraction from the plasma of healthy pregnant women*.

White Rose Research Online URL for this paper:  
http://eprints.whiterose.ac.uk/171716/

Version: Published Version

**Article:**  
Parker, V.L., Cushen, B.F., Gavriil, E. et al. (4 more authors) (2021) Comparison and optimisation of microRNA extraction from the plasma of healthy pregnant women. Molecular Medicine Reports, 23 (4). 258. ISSN 1791-2997  
https://doi.org/10.3892/mmr.2021.11897

**Reuse**  
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

**Takedown**  
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Comparison and optimisation of microRNA extraction from the plasma of healthy pregnant women

VICTORIA L. PARKER¹, BRYONY F. CUSHEN¹, ELEFHERIOS GAVRIL¹, BENJAMIN MARSHALL¹, SARAH WAITE¹, ALLAN PACEY¹ and PAUL R. HEATH²

¹Department of Oncology and Metabolism, The University of Sheffield, Sheffield S10 2SF; ²Sheffield Institute of Translational Neuroscience, The University of Sheffield, Sheffield S10 2HQ, UK

Received July 25, 2020; Accepted December 15, 2020

DOI: 10.3892/mmr.2021.11897

Abstract. Circulating microRNA (miRNA) biomarkers are implicated in the diagnosis, monitoring and prediction of various disease processes. Before embarking upon biomarker discovery, miRNA extraction techniques must first be optimised in the biofluid and population under study. Using plasma from a healthy pregnant woman, it was attempted to optimise and compare the performance of two commercially available miRNA extraction kits; Qiagen (miRNeasy Serum/Plasma) and Promega (Maxwell® RSC miRNA from Tissue or Plasma or Serum). Sample miRNA content (concentration and percentage) was assessed using Agilent Bioanalyzer Small RNA chips and reverse transcription-quantitative PCR (RT-qPCR) using four constitutively expressed miRNAs (hsa-miR-222-3p, hsa-let-7i-3p, hsa-miR-148-3p and hsa-miR-30e-5p). Quality control spike-ins monitored RNA extraction (UniSp2, 4 and 5) and cDNA synthesis (UniSp6, cel-miR-39-3p) efficiency. Optimisation approaches included: i) Starting volume of plasma; the addition of ii) Proteinase K; iii) a RNA bacteriophage carrier (MS2); and iv) a glycogen carrier. The two kits exhibited equivalence in terms of miRNA recovery based on Bioanalyzer and RT-qPCR \( \Delta \Delta \text{Cq} \) results. Optimisation attempts for both kits failed to improve upon miRNA content compared with standard methodology. Comparing the standard methodology, the Qiagen kit was more consistent (smaller variance of \( \Delta \Delta \text{Cq} \) values) compared with the Promega kit. The standard methodology of either kit would be suitable for the investigation of miRNA biomarkers in a healthy pregnant population.

Introduction

MicroRNA (miRNA) are a class of short, non-coding RNAs involved in post-transcriptional downregulation of protein expression in eukaryotic organisms, through silencing of target messenger RNAs (1-3). They are implicated in regulating approximately one third of the genome; controlling multiple cellular processes, including apoptosis (2-4), proliferation (2), differentiation (2-5) and development (3-6).

An expanding body of pre-clinical evidence has implicated altered miRNA expression profiles in several disease processes (2,5-10), with the potential to facilitate earlier diagnosis, disease monitoring and predict prognosis (3,8-10). Increasing literature is emerging concerning the role of placental-derived miRNAs in pregnancy, originating from three main clusters on chromosome 19 (C19MC, miR-371-3) and chromosome 14 (C14MC) (11,12). Altered miRNA profiles have been detected in both healthy pregnancy (changing across trimesters and compared to the non-pregnant state) (13-16) and pregnancies complicated by gestational hypertension (17,18), pre-eclampsia (19), diabetes (20,21) or congenital anomalies (22).

Given the potential clinical utility of miRNAs, accurate and efficient quantification is essential. The relative ease and safety of obtaining blood samples over tissue biopsies (23-25), as well as the stability of circulating miRNAs has focused much of the current research towards blood testing (3,26). However, due to the low concentration of free miRNAs in biofluids, variable findings between different starting media (serum vs. plasma) and the alteration of the miRNA profile by haemolysis, signalling or environmental exposures, robust results have proven difficult to obtain (26-30). Additionally, variability in the collection, storage and processing of samples can affect outcomes (27). Standardised procedures for all stages of miRNA quantification would minimise variability but are yet to be developed. Techniques that increase efficiency are favoured, as higher miRNA concentrations in the eluate facilitate quantification (27,31). miRNA extraction from biofluids is the prime source of intra-assay variation in miRNA quantification, highlighting the need for a robust, reproducible protocol (32-34).

To assist in miRNA extraction, there are several commercially available kits, yet many pre-clinical biomarker studies fail to acknowledge the variability introduced by these different methodologies, potentially contributing to poor replicability between studies and delaying progression into clinical practice. There is a paucity of literature concerning the optimal kit to answer the clinical question at hand, as media and kit
performance may vary between the patient population (males, females, pregnant or non-pregnant) and the disease state under investigation (25,35). Compounded by inter-patient variability within study samples, identifying the optimal methodology is extremely difficult (27,32,36,37). Factors including the starting volume of biofluid, use of glycogen, yeast or bacteriophage RNA carriers (e.g. MS2) and the addition of a serine protease (e.g. Proteinase K) to digest native proteins can all be modified to improve the yield and reproducibility of miRNA extraction (24); the effect of each being dependent on the extraction technique (24,31,38-42). Carriers are particularly useful when handling biofluids with low starting miRNA concentrations (e.g. human serum and plasma), as counterproductively, the extraction process itself loses a sizeable proportion of the sample miRNA content (39). Downstream analysis techniques may restrict the choice of carrier, as degraded RNA bacteriophages cannot be distinguished from sample RNA content using Next Generation Sequencing platforms (43), hence miRNA-free glycogen carriers are instead recommended for this application (45).

This study aimed to compare the relative efficiency of two commercially available miRNA extraction kits to determine the most suitable approach using human plasma derived from women with an uncomplicated, healthy pregnancy. Qiagen mirNeasy Serum/Plasma kit uses a well-known chloroform/phenol and column-based miRNA extraction system, whilst the Promega Maxwell® RSC miRNA from Tissue or Plasma or Serum kit employs a novel technique involving an automated paramagnetic particle mover to drive the RNA through binding, washing and elution steps. To our knowledge, in the published literature, a methodological investigation involving this patient group has never been performed, neither has a comparison of these two particular extraction kits. We additionally sought to optimise the performance of each kit through four methodological modifications varying the: (i) starting volume of plasma; the addition of (ii) Proteinase K; (iii) a RNA bacteriophage carrier (MS2); and (iv) a glycogen carrier.

Materials and methods

Sample collection. Blood was obtained from a healthy pregnant woman with an uncomplicated, low-risk pregnancy at 9 weeks’ gestation using 4.5 ml Sodium citrate vacutainer tubes (NSH Supply Chain). Standard venepuncture procedures were followed, according to the National Cancer Institute Early Detection Research Network, involving a 21-gauge needle to minimise haemolysis. Following collection, samples were kept upright and stored on ice (maintaining a temperature of ~4°C) to inhibit miRNA degradation by circulating RNases within whole blood and processed within 2 h. Samples were centrifuged at 1,900 x g for 10 min at 4°C with the recovered plasma supernatant aliquoted and immediately stored at -80°C. Following gentle thawing at room temperature, aliquots underwent a second centrifugation step (16,000 x g for 10 min at 4°C) to generate platelet poor plasma.

Ethical approval. Written patient consent was taken from participants, within the ethical approval obtained from the United Kingdom North East Newcastle and North Tyneside 1 NHS Research Ethics Committee (Reference 16/NE/0292) on 30/08/2016 and The Health Research Authority on 27/09/2016, with approved non-substantial (18/10/2018 and 01/05/2019) and substantial (12/12/2019) amendments (Table II).

miRNA extraction. miRNA was extracted from plasma samples using the: i) mirNeasy Serum/Plasma kit (217184; Qiagen) and ii) a prototype of the Maxwell® RSC miRNA from Tissue or Plasma or Serum kit (AS1680; Promega) (44) both with minor modifications. Standard manufacturer and optimised approaches were performed, modifying: i) starting volume of plasma; the addition of ii) Proteinase K; iii) a RNA bacteriophage carrier (MS2); and iv) a glycogen carrier (Figs. 1 and 2; Table I). In short, step (2) of the mirNeasy protocol was modified; UniSp2, UniSp4 and UniSp5 spike-in mix (reconstituted according to manufacturers’ instructions) (339390, RNA spike-in kit; Qiagen) (Table II) was diluted 1:1 into QIAzol lysis buffer, mixing thoroughly. 0.5 µl of spike-in mix was added per 100 µl of plasma in accordance with the manufacturer’s protocol. When required (Fig. 2; Table I), 1 µg per 200 µl of RNA bacteriophage MS2 (0.8 µg/µl) (10165948001; Roche Diagnostics GmbH) or 2 µg per 200 µl of RNA grade Glycogen (20 mg/ml) (R0551; Thermo Fisher Scientific, Inc.) was added to the dilute RNA spike-in and QIAzol lysis reagent mix, combining thoroughly. This mix was combined with the remaining volume of lysis buffer and step (4) of the protocol omitted.

The prototype Promega protocol with minor modifications was conducted as follows: Lyophilised DNase I was resuspended with 275 µl of nuclease free water, adding 5 µl of Blue Dye as a visual indicator, inverting or swirling to mix. Aliquots were produced, storing at 4°C (few weeks) or -20°C (longer storage). UniSp2, UniSp4 and UniSp5 spike-in mix (reconstituted according to manufacturers’ instructions) (339390, RNA spike-in kit, Qiagen) was diluted 1:1 into binding buffer. 0.5 µl of spike-in mix was added per 100 µl of plasma in accordance with the manufacturer’s protocol. When required (Fig. 2; Table I), 1 µg per 200 µl of RNA bacteriophage MS2 (0.8 µg/µl) (10165948001; Roche Diagnostics GmbH) or 2 µg per 200 µl of RNA grade Glycogen (20 mg/ml) (R0551; Thermo Fisher Scientific, Inc.) was added to the diluted spike-in mix, combining thoroughly. The spike-in +/- carrier molecule mix was then added to the remaining volume of binding buffer, mixing thoroughly. 100, 200 or 500 µl (Fig. 1; Table I) of pre-processed plasma (see Sample collection in Materials and methods section) was transferred to a 1.5 ml Eppendorf and 60 µl Proteinase K added, replacing Proteinase K with nuclease-free water when required (Fig. 2; Table I). This was then added to the binding buffer, spike-in +/- carrier molecules mix, vortexing for 10 sec. This sample lysate was then incubated at 37°C for 15 min. During this time, the Maxwell® Rapid Sample Concentrator (RSC) cartridges were loaded into the RSC deck tray, their seals removed, and the RSC plungers inserted into well 8 of the cartridges. 500 µl elution tubes were loaded into the deck and 60 µl nuclease-free water added to each. Ten microliters of reconstituted DNase I was added to well 4 (yellow) of the cartridges and following incubation, all of the sample lysate was transferred into well 1 of the cartridges. The Maxwell® RSC Instrument (AS4500; Promega) (45) instrument and the ‘RSC miRNA Tissue’ method was used to...
begin the automated purification run. Following processing, the eluate was stored at -80°C.

Five replicates were performed for each approach investigated. Extracted RNA was assessed for quality and quantity [miRNA/small RNA ratio (%) and miRNA concentration (pg/µl)] using an Agilent Small RNA Chip (5067-1548; Agilent Technologies) and 2100 Bioanalyzer (G2939Ba; Agilent Technologies) according to manufacturers’ instructions.

miRNA quantification. cDNA was synthesised using the miRCURY LNA RT kit (339340; Qiagen) with a total reaction volume of 10 µl and a minor modification. Specifically, during step (2), 0.5 µl of UniSp6 and cel-miR-39-3p spike-in mix, (339390, RNA spike-in kit; Qiagen) (Table II) was diluted 1:5 in nuclease free water and added to the RT reaction mix. Reverse transcription-quantitative PCR (RT-qPCR) was performed using the miRCURY LNA® SYBR® Green PCR kit (339346; Qiagen) and 14 miRNA primers (Table II). To

---

Table I. Standard and optimised microRNA extraction approaches.

| Kit       | Approach | Code | Plasma volume, µl | Proteinase K, µl | MS2, µg | Glycogen, µg |
|-----------|----------|------|-------------------|------------------|---------|--------------|
| Promega   | S        | A    | 500               | 60               | None    | None         |
|           | O        | B    | 500               | Replaced with NFH2O | None | None         |
|           | O        | C    | 500               | 60               | 2.5     | None         |
|           | O        | D    | 500               | Replaced with NFH2O | 2.5 | None         |
|           | O        | E    | 500               | 60               | None    | 5            |
|           | O        | F    | 500               | Replaced with NFH2O | None | 5            |
|           | O        | G    | 200               | 60               | None    | None         |
|           | O        | H    | 100               | 60               | None    | None         |
| Qiagen    | O        | B    | 200               | None             | None    | None         |
|           | O        | C    | 200               | 24               | 1       | None         |
|           | S        | D    | 200               | None             | 1       | None         |
|           | O        | E    | 200               | 24               | None    | 2            |
|           | O        | F    | 200               | None             | None    | 2            |
|           | O        | G    | 200               | 24               | None    | None         |
|           | O        | I    | 100               | None             | 0.5     | None         |

S, standard approach following manufacturers’ instructions/protocol as detailed in manuscript; O, optimised approach; NFH2O, nuclease-free water.

---

Table II. Description of the 14 miRNA primers used for reverse transcription-quantitative PCR.

| miRNA primer | Function                              | Sequence (5’-3’)
|--------------|---------------------------------------|------------------|
| UniSp2       | RNA extraction efficiency             | Unavailable       |
| UniSp4       | RNA extraction efficiency             | Unavailable       |
| UniSp5       | RNA extraction efficiency             | Unavailable       |
| UniSp6       | cDNA synthesis efficiency             | Unavailable       |
| cel-miR-39-3p| cDNA synthesis efficiency             | UCACCGGGUGUAAAUCAUCAGCUUG |
| hsa-miR-451a | Stably expressed miRNA used for       | AAACCGUUACAUUAUCAGUGU |
|              | normalisation and detection of haemolysis |                |
| hsa-miR-23a  | Stably expressed miRNA used for       | AUCACAAUUGCCAGGGAUUUCC |
|              | normalisation and detection of haemolysis |                |
| hsa-miR-423-3p| Stably expressed miRNA used for       | AGCUCCGGUGAGGCCCCCUCAGU |
|              | normalisation                         |                  |
| hsa-miR-103a-3p| Stably expressed miRNA used for       | AGCAGCAUUGUACAGGCUAUGA |
|              | normalisation                         |                  |
| hsa-miR-191-5p| Stably expressed miRNA used for       | CAACGGAAUCCCAAAACGACGCUG |
|              | normalisation                         |                  |
| hsa-miR-222-3p| Stably expressed miRNA of interest    | AGCUACAUCUGGCUACUGGGU |
|              |                                     |                  |
| hsa-let-7i-3p| Stably expressed miRNA of interest    | CUGCGCAAGCUACUCUGCCUUUGCU |
|              |                                     |                  |
| hsa-miR-148-3p| Stably expressed miRNA of interest    | UCAGUGCAUCACAGAAUUCUUGU |
|              |                                     |                  |
| hsa-miR-30e-5p| Stably expressed miRNA of interest    | UGUAACAAUCCUUGACUGGAAG |

miRNA/miR, microRNA.
minimise run-to-run variation, one replicate for each extraction approach (Table 1) was combined with every primer in duplicate upon each 384-well plate. A 2-step cycling qPCR protocol (95°C for 2 min followed by 40 cycles at 95°C for 10 sec and 56°C for 60 sec) was conducted using a Bio-Rad CFX96, Real-time C1000 Touch Thermal Cycler (Bio-Rad Laboratories, Ltd.). RT-qPCR involved no-template controls (no RNA template nor UniSp6/cel-miR-39-3p spike-ins) (NTC) run with all 14 primers and no-Reverse Transcriptase controls (NRTC) run with the hsa-miR-222-3p miRNA primer. Inhibition controls (no RNA template but UniSp2, 4 and 5 or UniSp6/cel-miR-39-3p spike-ins added) were also prepared to exclude spike-in contamination and run with miRNA primer hsa-miR-222-3p. Replicates QG1 and QB1 run with miRNA primer hsa-miR-451 were selected as inter-plate calibrators (IPC), and performed in duplicate upon each 384-well plate.

Data analysis
Outliers. Cq values were calibrated between plates using IPC as described by TATAA (46). Mean Cq values and variance of duplicates performed for each extraction approach were
calculated for the 14 miRNA primers. Outliers were identified and excluded (n=25) based upon a PCR efficiency of 1.9 for the mircury lna® SYBR® Green PCR kit and the anticipation of increasing Cq variance with decreasing miRNA concentration (47) (Table III).

Quality control. RNA extraction efficiency was measured using a unisp2,4 and 5 spike-in mix, whereby the concentration of unisp2>unisp4>unisp5 with a 100-fold magnitude change each time. Variance <2-3 cqs within each dataset and ΔCq of 5-7 between spike-ins was desired. cDNA synthesis efficiency markers (unisp6 and cel-mir-39-3p) were expected to have a target variance <2 cqs. Haemolysis levels were measured by ΔCq = mean Cq hsa-miR-23a-mean Cq hsa-miR-451, whereby ΔCq >5 or >7 indicated possible vs. high-risk of haemolysis, respectively, as guided by the manufacturer (23).

Relative expression. For each approach under investigation, normalisation was performed by calculating the geometric mean of three stably-expressed miRNAs in plasma, (hsa-miR-423-3p, hsa-miR-103a-3p and hsa-miR-191-5p). Relative quantification was based upon the ΔΔCq method (48), whereby the standard manufacturer's approach (A and D; Table I) was used as the control comparator for Promega and Qiagen samples respectively. Fold change was calculated by $2^{-\Delta \Delta Cq}$ and confidence intervals of $\Delta \Delta Cq$ log transformed by $2^{-\Delta \Delta Cq/\text{confidence interval}}$ (48).

Statistical analysis. Data were first checked for normality (Shapiro-Wilk test). For two-way comparisons (e.g. Bioanalyzer data), if the Gaussian distribution was satisfied, unpaired t-tests with Welch's correction (due to unequal standard deviations in the populations being compared) were performed, else the Mann-Whitney U test was used. For ≥3-way comparisons (e.g. comparing multiple approaches), Welch's ANOVA and post hoc Dunnett’s T3 multiple comparisons test were used. Statistics were performed in GraphPad Prism version 8, with P<0.05 deemed statistically significant.

Results

Bioanalyzer data. miRNA concentration and percentage did not significantly differ between the standardised or optimised Promega and Qiagen extraction approaches [A-I (Table I)] (P=0.09 and P=0.94, respectively, unpaired t-test with Welch's correction) (Fig. 3).

qPCR data

Quality control. Studying the Promega approaches, fold changes between the RNA extraction efficiency spike-ins were higher than desired, with unisp4-unisp2 of 8.05, unisp5-unisp4 of 5.63 (target 5-7) (Fig. 4A) and variance within the spike-ins ranging between 2.96 and 5.26 Cqs (target <3 Cq) (Fig. 4B). The Qiagen approaches were generally more in range, with unisp4-unisp2 of 6.69, unisp5-unisp4 of 7.88 (target 5-7) (Fig. 4A) and variance within the spike-ins ranging between 0.72 and 1.90 Cqs (target <3 Cq) (Fig. 4B). The Qiagen approaches were generally more in range, with unisp4-unisp2 of 6.69, unisp5-unisp4 of 7.88 (target 5-7) (Fig. 4A) and variance within the spike-ins ranging between 0.72 and 1.90 Cqs (target <3 Cq) (Fig. 4B). In both kits, Unisp6 Cq values were higher in the NTCs compared to samples (Promega P=0.0006; Qiagen P=0.0008; Mann-Whitney U test) (Fig. 4C). Despite this, a comparison of the global mean Unisp6 values across all samples vs. the inhibition controls suggested that RNA inhibitors did not significantly affect the PCR reaction (Promega P=0.07; Qiagen P=0.58; Mann-Whitney U test) (Fig. 4D). This was confirmed by comparing the global mean cel-miR-39-3p values across all samples vs. cel-miR-39-3p Cq values in the inhibition controls (Promega P=0.13; Qiagen P=0.52; Mann-Whitney U test) (Fig. 4E). Samples were not haemolysed in any approach analysed, with all values <7 (Fig. 4F) (23).
Comparison of standard vs. optimised approaches. i) Optimisation of plasma input volume. Analysing ΔΔCq values across all four miRNA of interest (Table II), only one miRNA (hsa-miR-222-3p) revealed a significant difference between plasma input volumes using the Promega extraction kit (Welch’s ANOVA test W=10.58, P=0.02). Upon post-hoc analysis, a significant difference existed between the two optimisation approaches: 200 µl input + proteinase K, no carriers (approach G; Table I) vs. 100 µl (+ proteinase K, no carriers, approach H), P=0.02 (Dunnett’s T3 multiple comparisons test).

No significant difference was found between the standard Qiagen miRNA extraction approach using 200 µl plasma [no proteinase K + MS2, (approach D)] vs. an optimised approach using 100 µl plasma [no proteinase K + MS2, (approach I)], with P>0.05 in all comparisons (Fig. 5).

Comparing Promega and Qiagen kits using all input volumes revealed a significant difference in only one miRNA (hsa-miR-222-3p) (Welch’s ANOVA test W=6.47, P=0.01), with a significant post-hoc analysis for the comparison between Promega 100 µl [+ proteinase K, no carriers, (approach H)] and Qiagen 200 µl [+ proteinase K, no carriers, (approach G)] (P=0.02, Dunnett’s T3 multiple comparisons test) (Fig. 5).
ii) Optimisation using Proteinase K, carriers MS2 and Glycogen. Comparing ΔΔCq from the standard [500 µl input + proteinase K, no carriers, (approach a)] vs. optimised approaches for the Promega kit, two miRNAs of interest showed significant changes (hsa-miR-148-3p, Welch’s ANOVA test W=17.29, P=0.0006 and hsa-miR-222-3p, W=3.87, P=0.046). Using hsa-miR-148-3p, post-hoc analysis revealed a significant difference comparing approach E (500 µl input + proteinase K + Glycogen) vs. approach F (500 µl input, no proteinase K + Glycogen) (P=0.04, Dunnett’s T3 multiple comparisons test); and approach C (500 µl input + proteinase K + MS2) vs. approach F (P=0.048, Dunnett’s T3 multiple comparisons test). For hsa-miR-222-3p, all post-hoc comparisons were not significant (P>0.05). Optimisation approaches using the Qiagen kit were not significant (P>0.05 in all comparisons) (Fig. 6). As none of the optimisation approaches performed upon either Promega or Qiagen kits improved upon the performance of standard approaches, further comparisons between kits were not performed.

Comparison of standard approaches Promega vs. Qiagen. A comparison between ΔΔCq values for the Promega standard approach [500 µl input + proteinase K, no carriers, (approach A)] vs. that of the Qiagen kit [200 µl input, no proteinase K + MS2, (approach D)] revealed no difference in performance across the four miRNA of interest (P>0.05).

To determine which kit yielded more consistent RT-qPCR results, the standard deviations of the ΔCq values for each miRNA were compared, using the standard approaches for each kit. Three out of four miRNAs were significantly different (let-7i-3p, P=0.03, hsa-miR-30e-5p, P<0.0001, mir-222-3p, P=0.003, unpaired t-test with Welch’s correction), with higher variances observed with the Promega kit (Fig. 7).

Discussion

The literature surrounding the optimal plasma miRNA extraction kit for use in a healthy, low-risk pregnant population is extremely limited, yet pre-clinical biomarker studies continue to be published, seemingly precluding adequate investigation of this crucial preliminary step. This study, comparing standard manufacturer’s methodology with attempts to optimise the efficiency of the Qiagen miRNeasy Serum/Plasma kit and the Promega Maxwell® RSC miRNA from Tissue or Plasma or Serum kit, has revealed equivalent performance across the majority of parameters investigated, including Bioanalyzer and RT-qPCR comparisons. Specifically, miRNA percentage,
concentration and the ΔΔCq values of four stably expressed miRNAs of interest using RTqPCR were not significantly different when comparing the kits in terms of their standardised vs. optimised methodologies. However, a difference did emerge concerning the consistency of the two kits, with the standard Qiagen miRNEasy method producing lower ΔCq standard deviation values for three out of four miRNAs under study.

Attempts to optimise the individual performance of the Qiagen kit were conclusively unsuccessful (no miRNAs differed), whilst at first glance, this may appear less definitive for the Promega kit, with 1-2 miRNAs differing between approaches. Crucially, however, none of the optimisation approaches approved upon standard manufacturer’s protocol, with differences only existing between the optimisation approaches themselves (200 vs. 100 µl input

Figure 6. Impact on the four miRNAs of interest when varying the use of Proteinase K, carrier molecules MS2 and glycogen (standard vs. optimised approaches) for the Promega and Qiagen miRNA extraction kits. Data are shown as the mean ± standard deviation. *P<0.05 (post hoc Dunnett’s T3 multiple comparisons test following Welch’s ANOVA). miRNA/miR, microRNA.
It would be wise to retain this step to maximize miRNA recovery, particularly when using different human samples, as the known differences in nuclease content and sample quality, particularly when using different human samples, it would be wise to retain this step to maximize miRNA recovery. Regarding input volume for the Promega kit, lower ΔΔCq values were obtained using a plasma volume of 100 vs. 200 µl for hsa-miR-222-3p, potentially suggesting that the kit performed more efficiently using lower starting volumes. However, this finding was not replicated amongst the remaining three miRNAs of interest. Previous studies using the miRNeasy biofluids kit found that doubling the input plasma volume (from 100 to 200 µl) does not equate to a proportional increase in miRNA recovery (24), due to protein clogging or saturation of the elution column, although others have failed to replicate this finding (49). It is possible that these inter-study disparities reflect the use of differing miRNA of interest and the varying ability of the kit to recover these molecules. The only way to subvert this issue is to protocol time limits, particularly within the column-based RNA binding, washing and elution steps. During this study, the authors could simultaneously process only 8-10 samples per protocol, whereas the Promega extraction kit uses a new, automated paramagnetic miRNA extraction technique which confers many advantages over traditional methods, not least minimizing the risks of sample cross-contamination; safety concerns associated with the handling of chemicals such as chloroform and phenol; issues surrounding column saturation or protein clogging; and technical variability between runs. Furthermore, the approach is highly efficient and enables 16 samples to be processed simultaneously within 70 min, which cannot be achieved using other commercially available kits (e.g. miRNeasy), largely due to protocol time limits, particularly within the column-based RNA binding, washing and elution steps. During this study, the authors could simultaneously process only 8-10 samples using the Promega kit (60 vs. 14 µl) is certainly advantageous to downstream applications, enabling more experimental investigations and replicates to be conducted with each individual sample, while facilitating standardisation between experiments and batch calibration. Lower elution volumes have been suggested to generate more concentrated samples (42), however this study and others have not found this (24). A final consideration is the financial cost, with the per sample cost being slightly lower with the Promega kit (£6.88 vs. £7.80 as of June 2020). Given the automated Promega protocol and reduced user-input, the
increased variance of the standard methodology compared to the Qiagen kit was surprising and could represent a batch extraction issue, as these samples were extracted separately to the other optimisation approaches.

The RNA extraction efficiency spike-ins within the Promega approaches generated higher than expected Cq values, which could be explained by the high degree of variance introduced by the different optimisation techniques, rather than the presence of RNAse contamination. This is supported by the high variance observed within the individual spike-in data for UniSp2, 4 and 5. However, further repeat experiments, potentially involving additional purification steps would be needed to confirm or refute this. We concur that the validity of this study was not diminished by the suggestion of cDNA synthesis inhibitors within the quality control analysis. Firstly, these inhibitors did not significantly impair the RT-qPCR upon statistical analysis and secondly, such quality control indicators are designed for samples extracted using the same standardised methodology, which was not the case in this study. It is clear that some optimisation approaches (e.g. H in Promega), were detrimental to miRNA extraction, generating Cq values >40 and hence the return of ‘no data’ for several replicates, which would have raised the variance of the quality control markers. The same applies for the RNA extraction quality control spike-ins. A limitation of this study is that a like-for-like comparison could not be made using the automated miRNA extraction system manufactured by Qiagen; (QIAcube, 9001793), and further studies should address this. Given the inter-individual variation within human samples (57), further work should include repeating these experiments using samples taken from several individuals to validate the findings. The equivalent performance of the two extraction kits sampled within this study, suggests that either would be suitable when evaluating or setting up studies concerning the miRNA profile of healthy pregnant women.

Acknowledgements

Not applicable.

Funding

VLP’s salary as a Clinical Research Fellow and the laboratory consumables within the present study were funded by two large grants (grant nos. CA154 and CA184) from Weston Park Cancer Charity, Sheffield, UK.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

VLP was involved in study conceptualization, data curation, methodology, project administration, formal analysis, funding acquisition, visualization and original draft preparation, and provided resources. BFC was involved in acquisition of data, methodology and original draft preparation. VLP and BFC confirmed the authenticity of the raw data. EG and BM were involved in acquisition of data, methodology and formal analysis. SW was involved in acquisition of data, methodology, resources, and supervision of the laboratory and writing. AP and PRH developed the methodology, provided resources, supervised the study, and reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethics approval was obtained from the North East Newcastle and North Tyneside 1 NHS Research Ethics Committee, UK, reference 16/NE/0292. Written consent was taken from all participants.

Patient consent for publication

Covered within the ethics application 16/N3/0292. No patient identifiable information is presented within the manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. Hobert O: Gene regulation by transcription factors and microRNAs. Science 319: 1785-1786, 2008.
2. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005.
3. Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev 87: 3-14, 2015.
4. He L, Thomson JM, Hemann MT, Hernandez-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GI, et al: A microRNA polyclastron as a potential human oncogene. Nature 435: 828-833, 2005.
5. Alrob OA, Khatib S and Naser SA: MicroRNAs 33, 122, and 208: A potential novel targets in the treatment of obesity, diabetes, and heart-related diseases. J Physiol Biochem 73: 307-314, 2017.
6. Creemers EE, Tijssen AJ and Pinto YM: Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110: 483-495, 2012.
7. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
8. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan K, Badran R, Hamade E, Daher A, Hussein N, ElDrania R, et al: Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 11: 31, 2013.
9. Rossbach M: Therapeutic implications of microRNAs in human cancer. J Nucleic Acids Investig: Feb 2, 2011 (Epub ahead of print), doi: 10.4081/jnai.2011.2200.
10. Mishra PK: MicroRNAs as promising biomarkers in cancer diagnosis. Biomark Res 2: 19, 2014.
11. Cai M, Kolluru GK and Ahmed A: Small molecule, big prospects: MicroRNA in pregnancy and its complications. J Pregnancy 2017: 6972732, 2017.
12. Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, Schoenleben M and Markert UR: Pregnancy-associated miRNA-clusters. J Reprod Immunol 97: 51-61, 2013.
13. Morales Prieto DM and Markert UR: MicroRNAs in pregnancy. J Reprod Immunol 88: 106-111, 2011.
14. Gilad S, Meiri E, Yoge Y, Benjamin S, Lebunony D, Yerushalmi N, Benjamin H, Kushmir T, Cholakh H, Melamed N, et al: Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148, 2008.
15. Kotlabova K, Doucha J and Hromadnikova I: Placental-specific microRNA in maternal circulation - identification of appropriate pregnancy-associated microRNAs with diagnostic potential. J Reprod Immunol 89: 185-191, 2011.
16. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW and Lo YM: Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54: 482-490, 2008.
17. Hromadnikova I, Kotlabova K, Ivankova K, Vedmedskaya Y and Krofta L: Profiling of cardiovascular and cerebrovascular disease associated microRNA expression in umbilical cord blood: Preanalytical hypertension: placenta and fetal growth restriction. Int J Cardiol 249: 402-409, 2017.

18. Hromadnikova I, Dvorakova L, Kotlabova K and Krofta L: The Prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci 20: 2972-2979, 2019.

19. Sheikh A, Small HY, Currie G and Delles C: Systematic review of micro-RNA expression in pre-eclampsia identifies a number of common pathways associated with the disease. PLoS One 11: e0160808, 2016.

20. Zhu Y, Tian F, Li H, Zhou Y, Lu J and Ge Q: Profiling maternal placental miRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynaecol Obstet 130: 49-53, 2015.

21. Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, Chen D, Xu J, Huo R, Dai J, et al: Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 6: e23925, 2011.

22. Yu Z, Han S, Hu P, Zhu C, Wang X, Qian L and Guo X: Potential role of maternal serum microRNAs as a biomarker for fetal congenital heart defects. Med Hypotheses 76: 424-426, 2011.

23. Blöndal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wang Terilum M and Dahlsvsen IK: Assessing sample and miRNA purity in serum and plasma or other biologics. Methods 59: SI-S6, 2013.

24. McAlexander MA, Phillips MJ and Witwer KW: Comparison of methods for mRNA extraction from plasma and quantitative recovery of RNA from cerebral spinal fluid. Front Genet 4: 83, 2013.

25. Ge Q, Shen Y, Tian F, Lu J, Bai Y and Lu Z: Profiling circulating microRNAs in maternal serum and plasma. Mol Med Rep 12: 3323-3330, 2015.

26. Ginge C, Clauss S, Boddam K, Jabbari R, Jabbari J, Risgaard B, Tomits P, Hildebrandt B, Kühl S, Walili R, et al: Stability of circulating blood-based MicroRNAs - pre-analytical methodological considerations. PLoS One 12: e0167969, 2017.

27. Brunet-Vega A, Pericay C, Quílez ME, Ramírez-Lázaro MJ, Calvet X and Larro S: Variability in microRNA recovery from plasma: Comparison of five commercial kits. Anal Biochem 488: 28-35, 2017.

28. Avissar-Whiting M, Veiga KR, Uhl KM, Maccani MA, Gagne LA, Moen EL and Marsit CJ: Bisphenol A exposure leads to specific microRNA alterations in placental cells. PLoS one 12: e0189165, 2017.

29. Maccani MA, Avissar-Whiting M, Banister CE, Mcgonigall B, Padbury JF and Marsit CJ: Maternal cigarette smoking during pregnancy is associated with downregulation of miR-16, miR-21, and miR-146a in the placenta. Epigenetics 5: 583-589, 2010.

30. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D and Galas DJ: Comparing the microRNA expression spectrum between serum and plasma. PLoS One 7: e41562, 2012.

31. Ban E, Chae DK, Yoo YS and Song EJ: An improvement of microRNA extraction efficiency in human plasma. Anal Bioanal Chem 65: 1132‑1140, 2019.

32. Tiberio P, Callari M, Angeloni V, Daidone MG and Appierto V: Challenges in using circulating miRNAs as cancer biomarkers. BioMed Res Int 2015: 734795, 2015.

33. McDonald JS, Milosevic D, Reddi HV, Grebe SK and Algeciras-Schimnich A: Analysis of circulating microRNA: Preamanalytical and analytical challenges. Clin Chem 57: 833-840, 2011.

34. Feng X, Liu Y and Wan N: Plasma microRNA detection standardization test. J Clin Lab Anal 34: e23058, 2020.

35. Foye C, Yan IK, David W, Shubhob N, Habboury Y, Chase L, Ryland K, Kesari V and Patel T: Comparison of miRNA quantitation by Nanostring in serum and plasma samples. PLoS One 12: e0189165, 2017.

36. Moldovan L, Batte KE, Trgovich J, Wesler J, Marsh CB and Piper M: Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 18: 371-390, 2014.

37. Kleten V, Neumann MHD, Di Pasquale F, Sprenger-Hausel M, Shaffer JM, Schlumpecher M, Heradean A, Betsum F, Amerlaan W, Af Hållström T, et al; CANCER-ID consortium: Multicenter evaluation of circulating plasma MicroRNA extraction technologies for the development of clinically feasible reverse transcription quantitative PCR and next-generation sequencing analytical work Flows. Clin Chem 65: 1132-1140, 2019.

38. Qiagen: miRCURY LNA microRNA PCR - Exosomes, serum/plasma and other biofluids samples handbook. 2017. https://www.qiagen. com/hl/resources/resourceatedetail?id=7a5f5f14-5f6d-4bdc-b2b2- 4266ec360158. 2017.

39. Andreasen D, Fog JU, Biggs W, Salomon J, Dahlsvsen IK, Baker A and Mouritzen P: Improved microRNA quantification in total RNA from clinical samples. Methods 50: S6-S9, 2010.

40. Ramón-Núñez LA, Martos L, Fernández-Pardo A, Oto J, Medina P, España F and Navarro S: Comparison of protocols and RNA carriers for plasma microRNA isolation. Unraveling RNA carrier influence on miRNA isolation. PLoS One 12: e0187005, 2017.

41. Danielson KM, Rubio R, Abderazzazq F, Das S and Wang YE: High throughput sequencing of extracellular RNA from human plasma. PLoS One 8: 16444, 2013.

42. Moret I, Sánchez-Izquierdo D, Iborra M, Tortosa L, Navarro-Puche A, Nép, Cervera J and Beltrán B: Assessing an improved protocol for plasma microRNA extraction. PLoS One 8: e28753, 2013.

43. Gautam A, Kumar R, Dimitrov G, Hoke A, Hammami R and Jett M: Identification of extracellular microRNA in archived serum samples by next-generation sequencing from RNA extracted using multiple methods. Mol Biol Rep 43: 1165-1178, 2016.

44. Promega: Maxwell® RSC microRNA Plasma and Serum Kit: Instructions for Use of Product AS1680. https://www.promega. co.uk/products/nucleic-acids/extractions/micro‑RNA‑extraction‑ Maxwell‑rsc‑microrna‑issue‑plasma‑serum‑kit/?catNum=AS1460/protocols. 2017.

45. Promega: Maxwell® RSC Instrument, AS4500. https://www. promega.co.uk/products/lab-automation/maxwell-instruments/ maxwell-rsc‑instrument/?catNum=AS4500 2017.

46. Interplate Calibrator, human variation compensation, SYBR Protocol. TATAA Biocenter AG, Göteborg, 2017.

47. de Ronde MW, Ruijter JM, Lanfear D, Baynes-Genis A, Kok MG, Creemers EE, Pinto YM and Pinto-Sietsma SJ: Practical data handling pipeline improves performance of qPCR-based circulating microRNA measurements. RNA 23: 811-821, 2017.

48. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta Ct) method. Methods 25: 402-408, 2001.

49. El-Khoury V, Piersson S, Kaoma T, Bernardin F and Berchem G: Assessing cellular and circulating microRNA recovery: The impact of the RNA isolation method and the quantity of input material. Sci Rep Jan 20, 2016 (Epub ahead of print). doi: 10.1038/srep19529. 2016.

50. Ford KL, Anwar M, Heys R, Ahmed EM, Caputo M, Game L, Reeves BC, Punjabi PP, Angelini GD, Petretto E, et al: Optimisation of laboratory methods for whole transcriptomic RNA analyses in human small ventricular biopsies and blood samples of clinical relevance. PLoS One 14: e0213685, 2019.

51. Rice J, Roberts H, Burton J, Pan J, States V, Rai SN and Galanduk S: Assay reproducibility in clinical studies of plasma microRNA. PLoS One 10: e0121948, 2015.

52. Tong RK, Macmahhon WS, Holland JD and Simpson DA: A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genomics 20: 446, 2019.

53. Meerson A and Ploug T: Assessment of six commercial plasma small RNA isolation kits using qRT-PCR and electrophoretic separation: higher recovery of microRNA following ultracentrifugation. Biol Methods Protoc 1: bwp003, 2016.

54. Burgos KL, Javaherian A, Bomporelli R, Ghaffari L, Rhodes S, Courtright A, Tembe W, Kim S, Metpally R and Van Keuren-Jensen K: Identification of extracellular microRNA in human cerebrospinal fluid by next-generation sequencing. RNA 19: 712-722, 2013.

55. Guo Y, Vickers K, Xiong Y, Zhao S, Sheng Q, Zhang P, Zhou W and Flynn CR: Comprehensive evaluation of extracellular small RNA isolation methods from serum in high throughput sequencing. BMC Genomics 18: 50, 2017.

56. Tan GW, Khoo AS and Tan LP: Evaluation of extraction kits and RT-qPCR systems adapted to high-throughput platform for circulating miRNAs. Sci Rep 5: 9430, 2015.

57. Keller A, Rouge T, Backes C, Ludwig N, Gisler F, Leidinger P, Langseth G and Meese E: Sources to variability in circulating human microRNA signatures. RNA Biol 14: 1791-1798, 2017.